These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 22612571)

  • 1. Overall treatment success after treatment of primary superficial basal cell carcinoma: a systematic review and meta-analysis of randomized and nonrandomized trials.
    Roozeboom MH; Arits AH; Nelemans PJ; Kelleners-Smeets NW
    Br J Dermatol; 2012 Oct; 167(4):733-56. PubMed ID: 22612571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Photodynamic therapy vs. topical imiquimod for treatment of superficial basal cell carcinoma: a subgroup analysis within a noninferiority randomized controlled trial.
    Roozeboom MH; Nelemans PJ; Mosterd K; Steijlen PM; Arits AH; Kelleners-Smeets NW
    Br J Dermatol; 2015 Mar; 172(3):739-45. PubMed ID: 25066012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor thickness and adnexal extension of superficial basal cell carcinoma (sBCC) as determinants of treatment failure for methylaminolevulinate (MAL)-photodynamic therapy (PDT), imiquimod, and 5-fluorouracil (FU).
    Roozeboom MH; van Kleef L; Arits AH; Mosterd K; Winnepenninckx VJ; van Marion AM; Nelemans PJ; Kelleners-Smeets NW
    J Am Acad Dermatol; 2015 Jul; 73(1):93-8. PubMed ID: 25935596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial.
    Arits AH; Mosterd K; Essers BA; Spoorenberg E; Sommer A; De Rooij MJ; van Pelt HP; Quaedvlieg PJ; Krekels GA; van Neer PA; Rijzewijk JJ; van Geest AJ; Steijlen PM; Nelemans PJ; Kelleners-Smeets NW
    Lancet Oncol; 2013 Jun; 14(7):647-54. PubMed ID: 23683751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Three-Year Follow-Up Results of Photodynamic Therapy vs. Imiquimod vs. Fluorouracil for Treatment of Superficial Basal Cell Carcinoma: A Single-Blind, Noninferiority, Randomized Controlled Trial.
    Roozeboom MH; Arits AHMM; Mosterd K; Sommer A; Essers BAB; de Rooij MJM; Quaedvlieg PJF; Steijlen PM; Nelemans PJ; Kelleners-Smeets NWJ
    J Invest Dermatol; 2016 Aug; 136(8):1568-1574. PubMed ID: 27113429
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conventional and combination topical photodynamic therapy for basal cell carcinoma: systematic review and meta-analysis.
    Collier NJ; Haylett AK; Wong TH; Morton CA; Ibbotson SH; McKenna KE; Mallipeddi R; Moseley H; Seukeran D; Ward KA; Mohd Mustapa MF; Exton LS; Green AC; Rhodes LE
    Br J Dermatol; 2018 Dec; 179(6):1277-1296. PubMed ID: 29889302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Photodynamic therapy in the treatment of basal cell carcinoma: a systematic review and meta-analysis.
    Wang H; Xu Y; Shi J; Gao X; Geng L
    Photodermatol Photoimmunol Photomed; 2015 Jan; 31(1):44-53. PubMed ID: 25377432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of topical imiquimod and fluorouracil vs. photodynamic therapy for treatment of superficial basal-cell carcinoma.
    Arits AH; Spoorenberg E; Mosterd K; Nelemans P; Kelleners-Smeets NW; Essers BA
    Br J Dermatol; 2014 Dec; 171(6):1501-7. PubMed ID: 24749843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma: a randomized controlled trial with at least 5-year follow-up.
    Roozeboom MH; Aardoom MA; Nelemans PJ; Thissen MR; Kelleners-Smeets NW; Kuijpers DI; Mosterd K
    J Am Acad Dermatol; 2013 Aug; 69(2):280-7. PubMed ID: 23566914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interventions for basal cell carcinoma of the skin.
    Bath-Hextall FJ; Perkins W; Bong J; Williams HC
    Cochrane Database Syst Rev; 2007 Jan; (1):CD003412. PubMed ID: 17253489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from a randomized vehicle-controlled phase III study in Europe.
    Schulze HJ; Cribier B; Requena L; Reifenberger J; Ferrándiz C; Garcia Diez A; Tebbs V; McRae S
    Br J Dermatol; 2005 May; 152(5):939-47. PubMed ID: 15888150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Confirmation of histological clearance of superficial basal cell carcinoma with multiple serial sectioning and Mohs' micrographic surgery following treatment with imiquimod 5% cream.
    Ezughah FI; Affleck AG; Evans A; Ibbotson SH; Fleming CJ
    J Dermatolog Treat; 2008; 19(3):156-8. PubMed ID: 18569271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-fold illumination in topical 5-aminolevulinic acid (ALA)-mediated photodynamic therapy (PDT) for superficial basal cell carcinoma (sBCC): A retrospective case series and cohort study.
    Kessels J; Hendriks J; Nelemans P; Mosterd K; Kelleners-Smeets N
    J Am Acad Dermatol; 2016 May; 74(5):899-906. PubMed ID: 26774689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thickness of superficial basal cell carcinoma (sBCC) predicts imiquimod efficacy: a proposal for a thickness-based definition of sBCC.
    McKay KM; Sambrano BL; Fox PS; Bassett RL; Chon S; Prieto VG
    Br J Dermatol; 2013 Sep; 169(3):549-54. PubMed ID: 23627639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Basal cell carcinoma: an evidence-based treatment update.
    Clark CM; Furniss M; Mackay-Wiggan JM
    Am J Clin Dermatol; 2014 Jul; 15(3):197-216. PubMed ID: 24733429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential Treatment of Superficial Basal Cell Carcinomas With Topical Methyl Aminolevulinate Photodynamic Therapy and Imiquimod 5% Cream: A Retrospective Study of Clinical and Cosmetic Outcomes.
    Logan IT; Kulakov EL; Perrett CM
    Dermatol Surg; 2020 Oct; 46(10):1272-1278. PubMed ID: 32011386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial: a critical appraisal.
    Lecluse LL; Spuls PI
    Br J Dermatol; 2015 Jan; 172(1):8-10. PubMed ID: 25581584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness and satisfaction with imiquimod for the treatment of superficial basal cell carcinoma in daily dermatological practice.
    Daudén E;
    J Eur Acad Dermatol Venereol; 2011 Nov; 25(11):1304-10. PubMed ID: 21348896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A cost analysis of photodynamic therapy with methyl aminolevulinate and imiquimod compared with conventional surgery for the treatment of superficial basal cell carcinoma and Bowen's disease of the lower extremities.
    Aguilar M; de Troya M; Martin L; Benítez N; González M
    J Eur Acad Dermatol Venereol; 2010 Dec; 24(12):1431-6. PubMed ID: 20456549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Local reactions to imiquimod in the treatment of basal cell carcinoma.
    Tandon Y; Brodell RT
    Dermatol Online J; 2012 Sep; 18(9):1. PubMed ID: 23031368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.